Total for the last 12 months
number of access : ?
number of downloads : ?
ID 114532
Takai, Atsuko Teikyo University
Kikuchi, Kentaro Teikyo University
Moritoki, Yuki Akita University
Matsumoto, Kotaro Teikyo University
Tsunashima, Hiromichi Teikyo University
Onda, Takeshi Teikyo University|Nippon Medical School
Kuniyoshi, Noriyuki Teikyo University|Nihon University
Nariyama, Tomoyuki Teikyo University
Ohyatsu, Sho Teikyo University
Kubota, Juri Teikyo University
Nagumo, Kozue Teikyo University
Sato, Shinpei Teikyo University
Hara, Masumi Teikyo University
Miyakawa, Hiroshi Teikyo University
Monosodium glutamate
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Short-chain fatty acids
Content Type
Journal Article
Background: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. Within the spectrum of NAFLD, non-alcoholic steatohepatitis (NASH) in combination with hepatic inflammation and fibrosis can lead to liver cirrhosis and hepatocellular carcinoma. Dysbiosis was reported to contribute to NASH pathogenesis. This study aimed to determine the effects of fructo-oligosaccharides (FOS) on steatohepatitis and visceral adiposity in an obese mouse model of NASH.
Methods: Twelve newborn C57BL/6 J male mice were subcutaneously injected with monosodium glutamate (MSG) to induce obesity on a conventional diet. Six mice were also administered 5% FOS via drinking water from 10 weeks of age. At 18 weeks, histological characteristics of the liver and epididymal fat were compared between the groups. Hepatic mRNA expression of lipid metabolism enzymes and SCFA in feces and sera were measured.
Results: Hepatic steatosis, inflammatory cell infiltration, and hepatocyte ballooning in the liver and increased hepatic mRNA expression of fatty acid synthase and glycerol-3-phosphate acyltransferase were observed in the MSG-treated mice. FOS treatment improved the liver pathology and blunted the increases in the mRNA expression levels of lipid metabolism enzymes. In addition, FOS inhibited adipocyte enlargement and formation of crown-like structures and reduced the M1 macrophage frequency in the epididymal fat of the MSG mice (39.4% ± 3.0% vs. 22.8% ± 0.7%; P = 0.001). FOS increased not only the fecal concentrations of n-butyric acid (0.04 ± 0.01 vs. 0.38 ± 0.14 mg/g, P = 0.02), propionic acid (0.09 ± 0.03 vs. 0.42 ± 0.16 mg/g, P = 0.02), and acetic acid (0.65 ± 0.16 vs. 1.48 ± 0.29 mg/g, P = 0.03) but also the serum concentration of propionic acid (3.9 ± 0.5 vs. 8.2 ± 0.5 μmol/L, P = 0.001).
Conclusions: FOS ameliorates steatohepatitis, visceral adiposity, and chronic inflammation by increasing SCFA production.
Journal Title
BMC Gastroenterology
Springer Nature|BioMed Central
Start Page
Published Date
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
Medical Sciences